These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19490823)

  • 21. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells.
    Chung SS; Kim M; Lee JS; Ahn BY; Jung HS; Lee HM; Park KS
    Am J Physiol Endocrinol Metab; 2011 Nov; 301(5):E912-21. PubMed ID: 21846907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome Proliferator-activated Receptor-γ Activation Augments the β-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-obese Diabetic Mice.
    Maganti AV; Tersey SA; Syed F; Nelson JB; Colvin SC; Maier B; Mirmira RG
    J Biol Chem; 2016 Oct; 291(43):22524-22533. PubMed ID: 27613867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiazolidinediones protect mouse pancreatic β-cells directly from cytokine-induced cytotoxicity through PPARγ-dependent mechanisms.
    Wang AP; Li X; Zheng Y; Liu BL; Huang G; Yan X; Liu Z; Zhou Z
    Acta Diabetol; 2013 Apr; 50(2):163-73. PubMed ID: 21153483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes.
    Gupta D; Peshavaria M; Monga N; Jetton TL; Leahy JL
    Diabetes; 2010 Jun; 59(6):1445-50. PubMed ID: 20332343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
    Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
    Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in beta cell function occur in prediabetes and early disease in the Lepr (db) mouse model of diabetes.
    Do OH; Gunton JE; Gaisano HY; Thorn P
    Diabetologia; 2016 Jun; 59(6):1222-30. PubMed ID: 27048248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
    Gastaldelli A; Ferrannini E; Miyazaki Y; Matsuda M; Mari A; DeFronzo RA
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E871-83. PubMed ID: 17106061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thiazolidinediones and inflammation.
    Consoli A; Devangelio E
    Lupus; 2005; 14(9):794-7. PubMed ID: 16218490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can thiazolidinediones delay disease progression in type 2 diabetes?
    Leiter LA
    Curr Med Res Opin; 2006 Jun; 22(6):1193-201. PubMed ID: 16846552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist.
    Kanda Y; Shimoda M; Hamamoto S; Tawaramoto K; Kawasaki F; Hashiramoto M; Nakashima K; Matsuki M; Kaku K
    Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E278-86. PubMed ID: 19920213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
    Vasudevan AR; Balasubramanyam A
    Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
    Meriden T
    Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis.
    Decker M; Hofflich H; Elias AN
    Diabetes Obes Metab; 2008 Aug; 10(8):617-25. PubMed ID: 17645549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
    Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clinical Significance of PPAR Gamma Agonism.
    Campbell IW
    Curr Mol Med; 2005 May; 5(3):349-63. PubMed ID: 15892654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-cell preservation with thiazolidinediones.
    Campbell IW; Mariz S
    Diabetes Res Clin Pract; 2007 May; 76(2):163-76. PubMed ID: 17052795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altering PPARgamma ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers.
    Samarasinghe SP; Sutanto MM; Danos AM; Johnson DN; Brady MJ; Cohen RN
    Obesity (Silver Spring); 2009 May; 17(5):965-72. PubMed ID: 19165156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.